Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Janux Therapeutics (JANX) EBITDA Margin: 2020-2025

Historic EBITDA Margin for Janux Therapeutics (JANX) over the last 4 years, with Sep 2025 value amounting to -234.98%.

  • Janux Therapeutics' EBITDA Margin rose 400466.00% to -234.98% in Q3 2025 from the same period last year, while for Sep 2025 it was -510.80%, marking a year-over-year decrease of 11591.00%. This contributed to the annual value of -637.48% for FY2024, which is 5649.00% up from last year.
  • Janux Therapeutics' EBITDA Margin amounted to -234.98% in Q3 2025, which was up 94.46% from -4,239.64% recorded in Q3 2024.
  • Janux Therapeutics' 5-year EBITDA Margin high stood at -79.25% for Q2 2024, and its period low was -4,239.64% during Q3 2024.
  • Moreover, its 3-year median value for EBITDA Margin was -638.89% (2023), whereas its average is -1,149.41%.
  • Its EBITDA Margin has fluctuated over the past 5 years, first plummeted by 377,547bps in 2024, then skyrocketed by 400,466bps in 2025.
  • Over the past 5 years, Janux Therapeutics' EBITDA Margin (Quarterly) stood at -848.39% in 2021, then soared by 30,980bps to -538.59% in 2022, then surged by 13,559bps to -403.01% in 2023, then tumbled by 377,547bps to -4,239.64% in 2024, then skyrocketed by 400,466bps to -234.98% in 2025.
  • Its EBITDA Margin was -234.98% in Q3 2025, compared to -4,239.64% in Q3 2024 and -79.25% in Q2 2024.